BRD2 and primary ovarian failure: This result was also reflected in the heterogeneity analysis of FSH, Farimani et al. [32] included a higher proportion of women aged 35 and above (50%), which undoubtedly led to the difficulty in reducing FSH levels, and led to high heterogeneity.It is consistent with the poor performance of PRP in diseases such as premature ovarian failure [33].